{ "@context": "https://clearank.com/llms.txt", "@type": "clearank:AssetAnalysis", "url": "https://clearank.com/etf/spdr-biotech-xbi/", "dataUrl": "https://clearank.com/etf/spdr-biotech-xbi/data.json", "title": "S&P Biotech (XBI) ETF Forecast & Price Target (2026)", "description": "AI analysis of SPDR S&P Biotech (XBI) ETF. Real-time price data, holdings & daily forecasts. Updated daily.", "headline": "State Street SPDR S&P Biotech ETF (XBI)", "published": "2026-06-19T09:13:33+00:00", "modified": "2026-09-27T06:01:44.824+00:00", "generated": "2026-09-27T15:23:05.776Z", "language": "en-US", "publisher": { "name": "CleaRank", "url": "https://clearank.com/" }, "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.", "asset": { "ticker": "XBI", "name": "State Street SPDR S&P Biotech ETF", "type": "ETF", "exchange": "NYSE", "currency": "USD", "sector": null, "industry": null, "country": "United States", "website": null }, "quote": { "price": 155.03, "previousClose": 156.05, "change": -1.02, "changePercent": -0.65, "open": 156.8, "high": 157.17, "low": 153.85001, "volume": 8234900, "averageVolume": 9705140, "marketCap": 0, "fiftyTwoWeekHigh": 169.89, "fiftyTwoWeekLow": 92.64, "marketOpen": false, "asOf": "2026-09-27T06:01:44.000Z" }, "statistics": { "pe": null, "eps": null, "dividendYield": 0.001780300601001216, "beta": null, "priceToSales": null, "priceToBook": null, "revenueTtm": 0, "grossMargin": null, "returnOnEquity": null }, "technicals": { "rsi": 36.29, "macd": -0.94, "sma50": 157.73, "sma200": 137.99, "rsiSignal": "Bearish", "trend": "Bullish", "pricePosition": "Bearish", "macdSignal": "Bearish", "rating": "Bearish" }, "analysis": { "rating": "Hold", "score": 55, "consensus": "Hold", "fairValue": null, "analystTarget": 159.68, "analystCount": null, "wallStreetConsensus": "", "generatedAt": "2026-09-27T06:01:44.000Z", "priceAtAnalysis": 155.029999, "volatility": { "daily": 2.04, "risk": "etf" } }, "tradePlan": { "bias": "Neutral", "conservativeEntry": 153.48, "aggressiveEntry": 155.03, "stopLoss": 148.51, "stopLossPercent": 3.24, "targets": [ 158.08, 161.15, 165.76 ] }, "projections": { "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets", "years": [ { "year": 2027, "downside10th": 110.98, "base": 167.2, "upside90th": 251.91 }, { "year": 2028, "downside10th": 101, "base": 180.33, "upside90th": 321.96 }, { "year": 2029, "downside10th": 95.63, "base": 194.49, "upside90th": 395.55 }, { "year": 2030, "downside10th": 92.41, "base": 209.76, "upside90th": 476.13 }, { "year": 2031, "downside10th": 90.48, "base": 226.23, "upside90th": 565.69 }, { "year": 2032, "downside10th": 89.41, "base": 244, "upside90th": 665.88 }, { "year": 2033, "downside10th": 88.98, "base": 263.16, "upside90th": 778.32 }, { "year": 2034, "downside10th": 89.04, "base": 283.82, "upside90th": 904.7 }, { "year": 2035, "downside10th": 89.51, "base": 306.11, "upside90th": 1046.82 }, { "year": 2036, "downside10th": 90.33, "base": 330.14, "upside90th": 1206.66 } ] }, "faqCount": 8, "sources": [ "TwelveData", "Wall Street consensus" ], "sections": [ { "id": "price", "title": "XBI Price Analysis" }, { "id": "market-metrics", "title": "Market Metrics", "facts": { "Open": "$156.80", "Day Range": "$153.85 to $157.17", "Prev Close": "$156.05", "Volume": "8.23M", "52-Week Range": "$92.64 to $169.89" } }, { "id": "mi-fund-facts", "title": "XBI Fund Facts", "text": [ "State Street SPDR S&P Biotech ETF is an exchange-traded fund that provides targeted exposure to U.S. biotechnology companies. It seeks to track the S&P Biotechnology Select Industry Index, using an equal-weighted approach that gives relatively balanced representation across the portfolio rather than concentrating heavily in the largest firms. The fund is designed for investors looking for broad access to the biotech segment of the healthcare market through a single security.", "Fund reference data as of Sep 27, 2026. Expense ratio and net assets are reported by the fund; returns are total returns and can differ from price change." ], "tables": [ { "caption": "", "columns": [ "Period", "XBI", "Category" ], "rows": [ { "label": "YTD", "cells": [ "33.41%", "-2.39%" ] }, { "label": "1 month", "cells": [ "10.55%", "1.70%" ] }, { "label": "3 months", "cells": [ "19.00%", "-3.03%" ] }, { "label": "1 year", "cells": [ "81.71%", "21.31%" ] }, { "label": "3 years", "cells": [ "27.36%", "6.58%" ] }, { "label": "5 years", "cells": [ "4.23%", "1.49%" ] }, { "label": "10 years", "cells": [ "10.62%", "8.56%" ] } ] } ] }, { "id": "analysis", "title": "XBI Analysis", "text": [ "XBI is currently trading below its 20-day and 50-day moving averages, with the 20-day EMA at 158.32 and the 50-day SMA at 157.73, signaling short-term bearish momentum. However, the ETF remains above its 200-day SMA of 137.99, indicating that the longer-term trend is still positive. The Relative Strength Index (RSI) is at 36.29, which is in bearish territory, suggesting a lack of buying pressure. The Stochastic indicator at 23.15 also points to oversold conditions, potentially signaling a near-term bounce. The current price of 155.03 is below the 52-week range, but the 200-day SMA provides a key support level.", "The 6-12 month outlook for XBI is cautiously optimistic, contingent on the broader biotechnology sector's performance and overall market sentiment. While the ETF is currently trading below key short-term moving averages, its position above the 200-day SMA suggests that the long-term uptrend may persist. Positive developments in drug pipelines, regulatory approvals, and a favorable macroeconomic environment could drive XBI higher. Conversely, increased regulatory scrutiny, disappointing clinical trial results, or a general market downturn could pressure the ETF's price." ], "lists": { "ProTips": [ "Monitor the performance of the S&P Biotechnology Select Industry Index for sector-wide trends.", "Consider the impact of regulatory news and clinical trial results on individual holdings within XBI.", "Given the sector's volatility, utilize risk management strategies such as setting stop-loss orders.", "Evaluate XBI's performance against its category averages to assess its relative strength.", "Understand that the equal-weighting methodology can lead to different performance characteristics compared to market-cap-weighted biotech ETFs." ] } }, { "id": "correlations", "title": "Market Correlations", "text": [ "How this etf moves relative to other assets", "Based on 1 year of daily price data. Correlations may vary over different time periods." ], "facts": { "Correlation with S&P 500 (SPY)": "+0.58", "Correlation with Nasdaq 100 (QQQ)": "+0.54", "Correlation with Bitcoin (BTC)": "+0.11", "Correlation with Gold (XAU)": "+0.21" } }, { "id": "key-statistics", "title": "Key Statistics", "text": [ "The State Street SPDR S&P Biotech ETF (XBI) is heavily concentrated in the Healthcare sector, with 99.28% of its assets allocated to this industry. The fund's equal-weighting methodology ensures that smaller biotechnology companies have a meaningful impact on performance, differentiating it from market-cap-weighted indices. The sector's performance has been volatile, as evidenced by the mixed trailing returns against its category. The fund's expense ratio is 0.35%, costing $35.00 per $10,000 invested, and it holds net assets of $11.40 billion. The high concentration in biotechnology presents both opportunities for significant growth and risks associated with sector-specific headwinds.", "The underlying biotechnology companies it holds are subject to the dynamic earnings environment of the healthcare sector. The sector's performance is often driven by drug trial results, regulatory approvals, and patent expirations, which can lead to significant stock price movements. The broad exposure of XBI means its aggregate performance reflects the overall health and innovation pipeline within the U.S. biotechnology industry. Investors should monitor the earnings trends of major biotech firms to gauge the sector's overall profitability and growth prospects.", "The primary risk for XBI is its high concentration in the biotechnology sector, making it susceptible to sector-specific downturns driven by regulatory changes, clinical trial failures, or shifts in healthcare policy. The equal-weighting approach also means that the failure of a few significant holdings could disproportionately impact the ETF's performance compared to a market-cap-weighted fund. Also, the biotech sector is known for its high volatility, which can lead to significant price swings." ], "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "Yield", "cells": [ "0.35%" ] }, { "label": "Day High", "cells": [ "$157.17" ] }, { "label": "Day Low", "cells": [ "$153.85" ] }, { "label": "52 Week High", "cells": [ "169.89" ] }, { "label": "52 Week Low", "cells": [ "92.64" ] } ] } ] }, { "id": "technical-indicators", "title": "Technical Indicators", "text": [ "Technical Rating Bearish RSI Bearish SMA Cross Bullish Price vs SMA Bearish MACD Bearish Golden Cross in effect with the 50-day SMA ($157.73) above the 200-day SMA ($137.99), price is trading below the 50-day SMA." ], "facts": { "RSI": "Bearish", "SMA Cross": "Bullish", "Price vs SMA": "Bearish", "MACD": "Bearish" }, "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "RSI (14)", "cells": [ "36.29" ] }, { "label": "MACD", "cells": [ "-0.94" ] }, { "label": "SMA 50", "cells": [ "157.73" ] }, { "label": "SMA 200", "cells": [ "137.99" ] } ] } ] }, { "id": "trade-plans", "title": "XBI Trade Plans", "text": [ "Specific entry, exit, and risk management levels", "Enter now if confident", "Volatility-Adjusted Stop Loss Calculated based on RSI (36.3) and current market volatility", "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3" ], "facts": { "TARGET 1": "$158.08", "TARGET 2": "$161.15", "TARGET 3": "$165.76", "STOP LOSS": "$148.51" } }, { "id": "seasonality", "title": "Seasonal Patterns", "text": [ "Historical monthly performance trends", "Based on 3 years of historical monthly returns" ], "facts": { "Average Jan return": "+2.41%", "Average Feb return": "-0.41%", "Average Mar return": "-5.16%", "Average Apr return": "+1.14%", "Average May return": "+0.01%", "Average Jun return": "+6.29%", "Average Jul return": "-0.62%", "Average Aug return": "+2.72%", "Average Sep return": "-0.95%", "Average Oct return": "-2.16%", "Average Nov return": "+5.36%", "Average Dec return": "-0.09%" } }, { "id": "risk", "title": "Risk & Volatility", "facts": { "Daily Volatility": "2.04%" }, "lists": { "Risk considerations": [ "Monitor position sizing based on current volatility levels", "Consider stop-loss placement beyond recent price range", "Diversification helps mitigate single-stock risk exposure" ] } }, { "id": "growth", "title": "Growth of $10,000", "text": [ "A $10,000 investment in XBI in September 2016 would be worth about $22,550 today, compared with about $35,782 for the same investment in the S&P 500 benchmark." ] }, { "id": "monte-carlo", "title": "Monte Carlo Projection (10yr)", "text": [ "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in XBI today could grow to about $21,295 by 2036 in the base case, with a bull case near $77,834 and a bear case around $5,826. Projections are statistical simulations, not guarantees." ] }, { "id": "price-prediction", "title": "XBI ETF Price Prediction: 2030", "text": [ "CleaRank's simulation projects a price near $210 for XBI by 2030 in the base case, from $155 today (1.4x over 4 years). The downside path ends near $92.41. These are outcomes of a Monte Carlo simulation run on XBI's historical return distribution, not price targets, and they assume no dividends are reinvested.", "Method: 10,000 simulated price paths using XBI's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice." ], "tables": [ { "caption": "XBI simulated price paths by year", "columns": [ "Year", "Downside (10th pct)", "Base case", "Upside (90th pct)" ], "rows": [ { "label": "2027", "cells": [ "$111", "$167", "$252" ] }, { "label": "2028", "cells": [ "$101", "$180", "$322" ] }, { "label": "2029", "cells": [ "$95.63", "$194", "$396" ] }, { "label": "2030", "cells": [ "$92.41", "$210", "$476" ] }, { "label": "2031", "cells": [ "$90.48", "$226", "$566" ] }, { "label": "2032", "cells": [ "$89.41", "$244", "$666" ] }, { "label": "2033", "cells": [ "$88.98", "$263", "$778" ] }, { "label": "2034", "cells": [ "$89.04", "$284", "$905" ] }, { "label": "2035", "cells": [ "$89.51", "$306", "$1,047" ] }, { "label": "2036", "cells": [ "$90.33", "$330", "$1,207" ] } ] } ] }, { "id": "people-also-watch", "title": "People Also Watch", "links": [ { "text": "IAI iShares U.S. Broker-Dealers & Securities Exchanges ETF NYSE $180.88 -0.11%", "url": "https://clearank.com/etf/ishares-broker-dealers-iai/" }, { "text": "GPIQ Goldman Sachs Nasdaq-100 Premium Income ETF NASDAQ $58.22 +0.33%", "url": "https://clearank.com/etf/gpiq-etf-analysis/" }, { "text": "XLU State Street Utilities Select Sector SPDR ETF NYSE $39.51 +0.38%", "url": "https://clearank.com/etf/utilities-xlu/" }, { "text": "NUKZ Range Nuclear Renaissance Index ETF NYSE $61.43 +0.13%", "url": "https://clearank.com/etf/nukz-etf-analysis/" }, { "text": "FCG First Trust Natural Gas ETF NYSE $29.20 -2.14%", "url": "https://clearank.com/etf/fcg-etf-analysis/" }, { "text": "IYR iShares U.S. Real Estate ETF NYSE $96.63 -0.19%", "url": "https://clearank.com/etf/iyr-etf-analysis/" }, { "text": "IWF iShares Russell 1000 Growth ETF NYSE $126.25 +0.50%", "url": "https://clearank.com/etf/iwf-etf-analysis/" }, { "text": "IHF iShares U.S. Healthcare Providers ETF NYSE $55.86 +1.62%", "url": "https://clearank.com/etf/ishares-us-healthcare-providers-ihf/" } ] }, { "id": "related-comparisons", "title": "Popular Comparisons", "links": [ { "text": "TSLA vs AMZN Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/tsla-vs-amzn/" }, { "text": "NXPI vs ON Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/nxpi-vs-on/" }, { "text": "COP vs OXY Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/cop-vs-oxy/" } ] }, { "id": "faq", "title": "Frequently Asked Questions" } ], "faq": [ { "question": "What is the expense ratio for the State Street SPDR S&P Biotech ETF (XBI)?", "answer": "The expense ratio for XBI is 0.35%, which translates to a cost of $35.00 per $10,000 invested annually. This fee covers the management and operational costs of the fund." }, { "question": "What sectors does the State Street SPDR S&P Biotech ETF (XBI) hold?", "answer": "XBI is heavily concentrated in the Healthcare sector, holding 99.28% of its assets in this industry. A small portion, 0.72%, is allocated to Financial Services." }, { "question": "How has the State Street SPDR S&P Biotech ETF (XBI) performed against its category?", "answer": "XBI has shown strong performance relative to its category, particularly over longer periods. For example, its 1-year return was 81.71% compared to the category's 21.31%, and its 10-year return was 10.62% versus the category's 8.56%." }, { "question": "What is the price prediction for XBI ETF in 2030?", "answer": "Based on Monte Carlo simulations, the projected base price for XBI in 2030 is $209.76, with a downside price of $92.41 and an upside price of $476.13. These figures represent statistical simulation outcomes, not guaranteed price targets." }, { "question": "What are the key technical levels for XBI?", "answer": "XBI is currently trading below its 20-day and 50-day moving averages, indicating short-term weakness. The 200-day moving average at $137.99 serves as a key support level, while the 50-day SMA at $157.73 acts as a resistance level." }, { "question": "What is the dividend yield for XBI?", "answer": "The dividend yield for XBI is approximately 0.35%, providing a modest income stream to investors. The annual dividend rate is $0.54." }, { "question": "How diversified is the State Street SPDR S&P Biotech ETF (XBI)?", "answer": "XBI is not broadly diversified as it is highly concentrated in the biotechnology segment of the healthcare sector, holding 99.28% of its assets within this industry. Its equal-weighting strategy provides diversification across various biotech companies rather than across different sectors." }, { "question": "What is the current RSI status for XBI?", "answer": "The current RSI for XBI is 36.29, which is interpreted as bearish momentum, indicating a lack of strong buying interest in the ETF." } ], "related": { "peopleAlsoWatch": [ { "ticker": "IAI", "name": "iShares U.S. Broker-Dealers & Securities Exchanges ETF NYSE", "price": "$180.88", "change": "-0.11%", "url": "https://clearank.com/etf/ishares-broker-dealers-iai/" }, { "ticker": "GPIQ", "name": "Goldman Sachs Nasdaq-100 Premium Income ETF NASDAQ", "price": "$58.22", "change": "+0.33%", "url": "https://clearank.com/etf/gpiq-etf-analysis/" }, { "ticker": "XLU", "name": "State Street Utilities Select Sector SPDR ETF NYSE", "price": "$39.51", "change": "+0.38%", "url": "https://clearank.com/etf/utilities-xlu/" }, { "ticker": "NUKZ", "name": "Range Nuclear Renaissance Index ETF NYSE", "price": "$61.43", "change": "+0.13%", "url": "https://clearank.com/etf/nukz-etf-analysis/" }, { "ticker": "FCG", "name": "First Trust Natural Gas ETF NYSE", "price": "$29.20", "change": "-2.14%", "url": "https://clearank.com/etf/fcg-etf-analysis/" }, { "ticker": "IYR", "name": "iShares U.S. Real Estate ETF NYSE", "price": "$96.63", "change": "-0.19%", "url": "https://clearank.com/etf/iyr-etf-analysis/" }, { "ticker": "IWF", "name": "iShares Russell 1000 Growth ETF NYSE", "price": "$126.25", "change": "+0.50%", "url": "https://clearank.com/etf/iwf-etf-analysis/" }, { "ticker": "IHF", "name": "iShares U.S. Healthcare Providers ETF NYSE", "price": "$55.86", "change": "+1.62%", "url": "https://clearank.com/etf/ishares-us-healthcare-providers-ihf/" } ], "comparisons": [ { "ticker": "TSLA vs AMZN Comparison", "name": "", "url": "https://clearank.com/compare/tsla-vs-amzn/" }, { "ticker": "NXPI vs ON Comparison", "name": "", "url": "https://clearank.com/compare/nxpi-vs-on/" }, { "ticker": "COP vs OXY Comparison", "name": "", "url": "https://clearank.com/compare/cop-vs-oxy/" } ], "Newly Tracked": [ { "ticker": "KEYS", "text": "Keysight Technologies, Inc.", "url": "https://clearank.com/stock/keys-stock-analysis/" }, { "ticker": "BRO", "text": "Brown & Brown Inc", "url": "https://clearank.com/stock/bro-stock-analysis/" }, { "ticker": "SYY", "text": "Sysco Corp.", "url": "https://clearank.com/stock/syy-stock-analysis/" }, { "ticker": "FIS", "text": "Fidelity National Information Services, Inc.", "url": "https://clearank.com/stock/fis-stock-analysis/" }, { "ticker": "EXC", "text": "Exelon Corp.", "url": "https://clearank.com/stock/exc-stock-analysis/" } ], "Top Movers (24h)": [ { "ticker": "SEI/USD", "text": "↑ 19.29%", "url": "https://clearank.com/crypto/sei-sei/" }, { "ticker": "WLD/USD", "text": "↑ 17.41%", "url": "https://clearank.com/crypto/worldcoin-wld/" }, { "ticker": "ETHFI/USD", "text": "↓ 13.68%", "url": "https://clearank.com/crypto/ethfi-usd-crypto-analysis/" }, { "ticker": "TON/USD", "text": "↑ 12.10%", "url": "https://clearank.com/crypto/toncoin-ton-usd/" }, { "ticker": "SUI/USD", "text": "↑ 11.97%", "url": "https://clearank.com/crypto/sui-sui-usd/" } ], "Also in Health ETFs": [ { "ticker": "IBB", "text": "iShares Biotechnology", "url": "https://clearank.com/etf/ishares-biotechnology-ibb/" }, { "ticker": "IHF", "text": "iShares U.S. Healthcare Providers", "url": "https://clearank.com/etf/ishares-us-healthcare-providers-ihf/" }, { "ticker": "IHI", "text": "iShares U.S. Medical Devices", "url": "https://clearank.com/etf/ihi-etf-analysis/" }, { "ticker": "XLV", "text": "Health Care Select Sector SPDR", "url": "https://clearank.com/etf/health-care-select-spdr-xlv/" } ] }, "schema": [ { "@context": "https://schema.org", "@graph": [ { "@type": "Place", "@id": "https://clearank.com/#place", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" } }, { "@type": "Organization", "@id": "https://clearank.com/#organization", "name": "CleaRank", "alternateName": "CleaRank Financial AI", "url": "https://clearank.com", "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.", "slogan": "Clear data. Honest analysis.", "logo": { "@type": "ImageObject", "@id": "https://clearank.com/#logo", "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "caption": "CleaRank", "inLanguage": "en-US", "width": "336", "height": "153" }, "image": { "@id": "https://clearank.com/#logo" }, "sameAs": [ "https://x.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank", "https://t.me/clearank" ], "email": "info@clearank.com", "contactPoint": [ { "@type": "ContactPoint", "contactType": "customer support", "email": "info@clearank.com", "url": "https://clearank.com/contact/", "availableLanguage": "en" } ], "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" }, "location": { "@id": "https://clearank.com/#place" }, "knowsAbout": [ "stock analysis", "ETF analysis", "cryptocurrency analysis", "forex trading", "trading simulation", "trade journaling", "position sizing", "risk management", "prop firm challenges", "online broker regulation" ], "publishingPrinciples": "https://clearank.com/editorial-code/", "ethicsPolicy": "https://clearank.com/editorial-code/", "ownershipFundingInfo": "https://clearank.com/about-us/", "owns": { "@id": "https://clearank.com/#app" }, "founder": { "@id": "https://clearank.com/writer/shaundavidb/#person" } }, { "@type": "WebSite", "@id": "https://clearank.com/#website", "url": "https://clearank.com", "name": "CleaRank", "publisher": { "@id": "https://clearank.com/#organization" }, "inLanguage": "en-US" }, { "@type": "ImageObject", "@id": "https://clearank.com/wp-content/uploads/2026/06/xbi-analysis-2026-06.png", "url": "https://clearank.com/wp-content/uploads/2026/06/xbi-analysis-2026-06.png", "width": "1280", "height": "720", "caption": "SPDR S&P Biotech ETF (XBI) ETF performance and holdings analysis for June 2026", "inLanguage": "en-US" }, { "@type": "BreadcrumbList", "@id": "https://clearank.com/etf/spdr-biotech-xbi/#breadcrumb", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://clearank.com", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://clearank.com/etf/spdr-biotech-xbi/", "name": "SPDR S&P Biotech ETF (XBI) Analysis" } } ] }, { "@type": "WebPage", "@id": "https://clearank.com/etf/spdr-biotech-xbi/#webpage", "url": "https://clearank.com/etf/spdr-biotech-xbi/", "name": "S&P Biotech (XBI) ETF Forecast & Price Target (2026)", "datePublished": "2026-06-19T09:13:33+00:00", "dateModified": "2026-09-27T06:01:44+00:00", "isPartOf": { "@id": "https://clearank.com/#website" }, "primaryImageOfPage": { "@id": "https://clearank.com/wp-content/uploads/2026/06/xbi-analysis-2026-06.png" }, "inLanguage": "en-US", "breadcrumb": { "@id": "https://clearank.com/etf/spdr-biotech-xbi/#breadcrumb" }, "reviewedBy": { "@id": "https://clearank.com/writer/shaundavidb/#person" } }, { "@type": "Person", "@id": "https://clearank.com/writer/shaundavidb/#person", "name": "Shaun David", "jobTitle": "Co-Founder", "url": "https://clearank.com/writer/shaundavidb/", "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg", "sameAs": [ "https://www.linkedin.com/in/shaun-david-697b5817a/" ], "worksFor": { "@id": "https://clearank.com/#organization" } }, { "@type": "Article", "@id": "https://clearank.com/etf/spdr-biotech-xbi/#richSnippet", "headline": "S&P Biotech (XBI) ETF Forecast & Price Target (2026)", "name": "S&P Biotech (XBI) ETF Forecast & Price Target (2026)", "description": "AI analysis of SPDR S&P Biotech (XBI) ETF. Real-time price data, holdings & daily forecasts. Updated daily.", "datePublished": "2026-06-19T09:13:33+00:00", "dateModified": "2026-09-27T06:01:44+00:00", "author": { "@id": "https://clearank.com/#organization" }, "publisher": { "@id": "https://clearank.com/#organization" }, "publishingPrinciples": "https://clearank.com/editorial-code/", "about": { "@type": "InvestmentFund", "name": "State Street SPDR S&P Biotech ETF", "identifier": [ { "@type": "PropertyValue", "propertyID": "tickerSymbol", "value": "XBI" }, { "@type": "PropertyValue", "propertyID": "exchange", "value": "NYSE" } ], "description": "State Street SPDR S&P Biotech ETF is an exchange-traded fund that provides targeted exposure to U.S. biotechnology companies. It seeks to track the S&P Biotechnology Select Industry Index, using an equal-weighted approach that gives relatively balanced representation across the portfolio rather than", "provider": { "@type": "Organization", "name": "State Street Global Advisors" } }, "isPartOf": { "@id": "https://clearank.com/etf/spdr-biotech-xbi/#webpage" }, "image": { "@id": "https://clearank.com/wp-content/uploads/2026/06/xbi-analysis-2026-06.png" }, "inLanguage": "en-US", "mainEntityOfPage": { "@id": "https://clearank.com/etf/spdr-biotech-xbi/#webpage" } } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the expense ratio for the State Street SPDR S&P Biotech ETF (XBI)?", "acceptedAnswer": { "@type": "Answer", "text": "The expense ratio for XBI is 0.35%, which translates to a cost of $35.00 per $10,000 invested annually. This fee covers the management and operational costs of the fund." } }, { "@type": "Question", "name": "What sectors does the State Street SPDR S&P Biotech ETF (XBI) hold?", "acceptedAnswer": { "@type": "Answer", "text": "XBI is heavily concentrated in the Healthcare sector, holding 99.28% of its assets in this industry. A small portion, 0.72%, is allocated to Financial Services." } }, { "@type": "Question", "name": "How has the State Street SPDR S&P Biotech ETF (XBI) performed against its category?", "acceptedAnswer": { "@type": "Answer", "text": "XBI has shown strong performance relative to its category, particularly over longer periods. For example, its 1-year return was 81.71% compared to the category's 21.31%, and its 10-year return was 10.62% versus the category's 8.56%." } }, { "@type": "Question", "name": "What is the price prediction for XBI ETF in 2030?", "acceptedAnswer": { "@type": "Answer", "text": "Based on Monte Carlo simulations, the projected base price for XBI in 2030 is $209.76, with a downside price of $92.41 and an upside price of $476.13. These figures represent statistical simulation outcomes, not guaranteed price targets." } }, { "@type": "Question", "name": "What are the key technical levels for XBI?", "acceptedAnswer": { "@type": "Answer", "text": "XBI is currently trading below its 20-day and 50-day moving averages, indicating short-term weakness. The 200-day moving average at $137.99 serves as a key support level, while the 50-day SMA at $157.73 acts as a resistance level." } }, { "@type": "Question", "name": "What is the dividend yield for XBI?", "acceptedAnswer": { "@type": "Answer", "text": "The dividend yield for XBI is approximately 0.35%, providing a modest income stream to investors. The annual dividend rate is $0.54." } }, { "@type": "Question", "name": "How diversified is the State Street SPDR S&P Biotech ETF (XBI)?", "acceptedAnswer": { "@type": "Answer", "text": "XBI is not broadly diversified as it is highly concentrated in the biotechnology segment of the healthcare sector, holding 99.28% of its assets within this industry. Its equal-weighting strategy provides diversification across various biotech companies rather than across different sectors." } }, { "@type": "Question", "name": "What is the current RSI status for XBI?", "acceptedAnswer": { "@type": "Answer", "text": "The current RSI for XBI is 36.29, which is interpreted as bearish momentum, indicating a lack of strong buying interest in the ETF." } } ] } ] }